A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
The U.S. Food and Drug Administration has approved a new drug for adults with schizophrenia,  the FDA announced Thursday.